

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 0 904 774 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**31.03.1999 Bulletin 1999/13**

(51) Int Cl.<sup>6</sup>: **A61K 7/48, A61K 31/05**

(21) Application number: **98307523.5**

(22) Date of filing: **16.09.1998**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

Designated Extension States:

**AL LT LV MK RO SI**

(30) Priority: **23.09.1997 US 59625 P**

(71) Applicant: **Pfizer Products Inc.**

**Groton, CT 06340-5146 (US)**

(72) Inventor: **Hu, Lan**

**Dix Hills, New York 11746 (US)**

(74) Representative: **Hayles, James Richard et al**

**Pfizer Limited,  
Patents Department,  
Ramsgate Road  
Sandwich Kent CT13 9NJ (GB)**

(54) **Resorcinol derivatives**

(57) The present invention relates to the use of cer-      tain resorcinol derivatives as skin lightening agents.

**EP 0 904 774 A1**

## Description

[0001] The present invention relates to the use of certain resorcinol derivatives as skin lightening agents.

[0002] The terms "lightening agent" and "depigmentation agent" are used interchangeably throughout this document.

5 [0003] Skin color in humans arises from a complex series of cellular processes which are carried out within a unique population of cells called melanocytes. Melanocytes are located in the lower part of the epidermis, and their function is to synthesize a pigment, melanin, which protects the body from the damaging effects of ultraviolet radiation.

[0004] When skin is exposed to ultraviolet radiation, such as that contained in sunlight, melanocytes increase their synthesis of melanin. Melanin is deposited in melanosomes, which are vesicles found within the cell. The melanosomes  
10 are extruded from the cell and carried to the surface of the skin by keratinocytes, which internalize the melanin containing melanosomes. The end result is that the visible layers of the skin exhibit a brown color typically known as a "tan". The darkness of the color observed in the skin is proportionate to the amount of melanin synthesized by melanocytes and transferred to the keratinocytes.

[0005] The mechanism by which skin pigmentation is formed, melanogenesis, is particularly complex and schematically involves the following main steps: Tyrosine→L-Dopa→Dopaquinone→Dopachrome→Melanins. The first two reactions in this series are catalyzed by the enzyme tyrosinase. The activity of tyrosinase is promoted by the action of α-melanocyte stimulating hormone or UV rays to have melanin eventually formed as chromatism in the skin. It is well established that a substance has a depigmenting effect if it acts directly on the vitality of the epidermal melanocytes where melanogenesis normally occurs and/or if it interferes with one of the stages in melanin biosynthesis. The active  
20 compounds that are employed in the various methods and compositions of this invention inhibit tyrosinase and thus inhibit or decrease melanin biosynthesis.

[0006] There is a strong demand for agents which enable acquired deposition sites, such as spots or freckles, to be restored to a normal skin color. For this purpose, a variety of agents and methods have been developed and put on the market. Examples of such methods are (a) a method wherein vitamin C (L-ascorbic acid) having good reducing  
25 ability is administered orally in large amounts, (b) a method wherein glutathione is administered parenterally; (c) a method wherein a peroxide, such as hydrogen peroxide, zinc peroxide, sodium peroxide and the like, which is believed to have the bleaching action of melamine, is administered; and (d) a method wherein vitamin C or cysteine is administered topically in the form of an ointment, cream, lotion or the like. Vitamin C has a problem with respect to stability and becomes so unstable in water-containing systems that they will cause changes in odor and color. Thiol compounds  
30 such as glutathione and cysteine do not exhibit a satisfactory depigmental effect since the development of the effect is very slow.

[0007] The substances in widest use at the present time as depigmentors are, in particular, hydroquinone and its derivatives, particularly its ethers such as hydroquinone monomethyl ether. These compounds, while effective, are known to produce side effects, that can be dangerous. Hydroquinone, use of which is limited to a concentration of 2%,  
35 is both irritating and cytotoxic to the melanocyte.

[0008] United States Patent 4,526,179 refers to certain hydroquinone fatty esters that have good activity and are less irritating and more stable than hydroquinone.

[0009] Japanese Patent Application No. 27909/86 refers to other hydroquinone derivatives that do not have the drawbacks of hydroquinone but that have relatively poor efficacy.

40 [0010] United States Patent 5,449,518 refers to 2,5-dihydroxyphenyl carboxylic acid derivatives as skin depigmentation agents.

[0011] European Patent Application EP 341.664A1 refers to certain resorcinol derivatives as tyrosinase inhibitors and skin depigmentation agents.


[0012] The use of topical depigmentation agents that have good efficacy and are harmless is particularly desirable for  
45 treating the following: regional hyperpigmentation caused by melanocytic hyperactivity, such as idiopathic melasma occurring either during pregnancy (mask of pregnancy or chloasma) or secondary to estrogen-progesterone contraception; local hyperpigmentation caused by benign melanocytic hyperactivity and proliferation such as lentigo senilis or liver spots; accidental hyperpigmentation such as postlesional photosensitization and scarring; and certain forms of leukoderma such as vitiligo where, if the injured skin cannot be repigmented, the residual zones of normal skin are  
50 depigmented to impart a homogeneous white color to the entire skin.

[0013] The resorcinol derivatives of formula I, which are defined below and used in the various methods and compositions of this invention, are useful in the treatment of the foregoing dermatological conditions as well as other dermatological conditions, some of which are referred to later in this document, for which the subject being treated desires, for medicinal or cosmetic purposes, to lighten or reduce the pigmentation of the skin affected by the condition.

55 [0014] The resorcinol derivatives of formula I are also useful for the treatment of inflammatory disorders such as psoriasis and acne.

## Summary of Invention

[0015] The invention relates to the use of 4-cycloalkyl resorcinols having the formula:



wherein X is hydrogen; OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above.

n is 0 to 3; and

the dashed line indicates an optional double bond at that position.

[0016] The present invention also relates to the pharmaceutically acceptable acid addition and base salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1-methylene-bis-(2-hydroxy-3-naphthoate)) salts.

[0017] The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

[0018] The term "aryl", as used herein, refers to phenyl or naphthyl optionally substituted with one or more substituents, preferably from zero to two substituents, independently selected from halogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di-[(C<sub>1</sub>-C<sub>6</sub>)alkyl]amino, nitro, cyano and trifluoromethyl.

[0019] The term "one or more substituents", as used herein, refers to a number of substituents that equals from one to the maximum number of substituents possible based on the number of available bonding sites.

[0020] The "halogen", as used herein, unless otherwise indicated, include chloro, fluoro, bromo and iodo.

[0021] Examples of more specific embodiments of the present invention include:

- (a) compounds of the formula I wherein a single bond connects the two carbon atoms at the dashed line;
- (b) compounds of the formula I wherein n is one;
- (c) compounds of the formula I wherein X is hydrogen;
- (d) compounds of the formula I wherein X is hydrogen, methyl or ethyl;
- (e) compounds of the formula I wherein n is zero;
- (f) compounds of the formula I wherein n is two; and
- (g) compounds of the formula I wherein X is benzyloxy.

[0022] In a preferred embodiment, the compound of formula I is 4-cyclohexylresorcinol or 4-cyclopentylresorcinol.

[0023] The present invention also relates to a topical pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in lightening skin or reducing the pigmentation of skin, and a pharmaceutically acceptable carrier.

[0024] The present invention also relates to a method of lightening skin or reducing the pigmentation of skin in a human, comprising administering to said human an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in lightening skin or reducing the pigmentation of skin.

[0025] The present invention also relates to a topical pharmaceutical composition for inhibiting tyrosinase in a human comprising a tyrosinase inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable

salt thereof, and a pharmaceutically acceptable carrier.

**[0026]** The present invention also relates to a method of inhibiting tyrosinase in a human, comprising administering to said mammal a tyrosinase inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

5 **[0027]** The present invention also relates to a topical pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising a tyrosinase inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

**[0028]** The present invention also relates to a method of lightening skin or reducing the pigmentation of skin in a human, comprising administering to said human a tyrosinase inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

10 **[0029]** The present invention also relates to a topical or transdermal pharmaceutical composition for the treatment of an inflammatory disorder such as acne or psoriasis in a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder, and a pharmaceutically acceptable carrier.

15 **[0030]** The present invention also relates to a method of treating inflammatory disorders such as psoriasis and acne in a human, comprising administering to said human an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.

**[0031]** The present invention also relates to a topical or transdermal pharmaceutical composition for the treatment of an inflammatory disorder such as acne or psoriasis in a human, comprising a tyrosinase inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20 **[0032]** The present invention also relates to a method of treating inflammatory disorders such as psoriasis and acne in a human, comprising administering to said human a tyrosinase inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

25 **[0033]** Compounds of formula I may contain chiral centers and therefore may exist in different enantiomeric and diastereomeric forms. This invention relates to all optical isomers and all stereoisomers of compounds of the formula I and mixtures thereof, and to all pharmaceutical compositions and methods of treatment defined above that contain or employ them, respectively.

30 **[0034]** Formula I above includes compounds identical to those depicted but for the fact that one or more hydrogen, carbon or other atoms are replaced by isotopes thereof. Such compounds may be useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays.

#### Detailed Description of the Invention

35 **[0035]** The compounds of the formula I may be prepared as described in the following reaction schemes and discussion. Unless otherwise indicated, X, n, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> and structural formula I in the reaction schemes and discussion that follow are defined as above.

40

45

50

55

SCHEME 1

5

10

15

20

25

30


35

40


45

50


55



+



(1)



I

SCHEME 2

5

10

15

20

25

30


35

40

45

50

55



## SCHEME 3

5

(5) or (6)

1.  $R^2COCl$ 

2. Deprotection


10

1.  $R^1I$ 


2. Deprotection

15

20

(X=OCOR<sup>2</sup>)

25



30

35

40

(X = OR<sup>1</sup>)

45

50

55

## SCHEME 4

5

10

15

20


25

30

35

40

45



[0036] Reaction schemes 1 through 4 illustrate various methods of synthesizing compounds of the formula I.

[0037] Referring to Scheme 1, compounds of the formula I can be formed by heating resorcinol with the appropriate cycloalkanol of formula (1) using polyphosphoric acid (PPA) or another suitable acidic catalyst. When PPA is used, the reaction is typically carried out using one to three equivalents of the alcohol in neat PPA at a temperature between about 100°C and about 160°C.

[0038] Referring to Scheme 2, the starting material of formula (2) can be obtained by protecting commercially available 4-bromoresorcinol. Suitable protecting groups (PG) are methyl (CH<sub>3</sub>) and benzyl (CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), and can be introduced by conventional methods that are well known to those of skill in the art. For example, the methyl and benzyl protected compounds may be obtained by alkylating 4-bromoresorcinol with two equivalents of methyl iodide or benzyl bromide, respectively and five equivalents of potassium carbonate in an acetone solvent at about room temperature.



[0039] Compounds of the general formula (3) are known and may be obtained using conventional methods well known to those of skill in the art. Compounds of the formula (4) can be obtained by reaction of compounds of the formula (2) and those of the formula (3) under Heck conditions. Specifically, the Heck reaction may be carried out using palladium (II) acetate (one mole percent), triphenylphosphine (two mole percent) and triethylamine (one equivalent), and heating the reaction mixture in a suitable solvent (e.g., N,N-dimethylformamide (DMF)) at a temperature from about 80°C to about 130°C. Reduction of compounds of the formula (4) with di(isobutyl)aluminum hydride (DIBAL-H) gives the corresponding allylic alcohols of formula (5). Hydrogenolysis of alcohols of formula (5), for example, using hydrogen gas and a metal catalyst such as palladium-on-charcoal in ethanol at about room temperature, yields the saturated analogues of formula (6), which can then be deprotected under suitable conditions to give the correspondent resorcinols of formula I wherein X is hydroxy. Alternatively, similar deprotection of the allylic alcohols of formula (5) yields the corresponding resorcinols of formula I wherein X is hydroxy.

[0040] Referring to Scheme 3, esterification of compounds of the formula (5) or (6) with an appropriate acyl chloride ( $R^2COCl$ ) under conventional conditions well known to those of skill in the art, followed by suitable deprotection, gives the corresponding compounds of formula I wherein X is  $OCOR^2$ . For example, esterification can be accomplished by reacting the alcohol of formula (5) or (6) with one equivalent of an acyl chloride and one equivalent of triethylamine in dichloromethane at about room temperature. Alkylation of compounds of the formula (5) or (6) with an alkyl iodide ( $R^1I$ ) in the presence of base (using, for example, one equivalent of sodium hydride and the desired alkylating agent in the form of an alkyl chloride, bromide or iodide, in tetrahydrofuran (THF) at about the reflux temperature), using methods well known to those of skill in the art, followed by deprotection, gives the corresponding compounds of the formula I wherein X is  $OR^1$ .

[0041] Referring to Scheme 4, transformation of the alcohol function in compounds of the formula (5) or (6) into a suitable leaving group (L), such as, for example, mesylate, gives the corresponding compounds of formula (7). Formation of the mesylate may be carried out using one equivalent of mesyl chloride and one equivalent of triethylamine in dichloromethane at about room temperature. Displacement with a thioalkoxide (for example, by reacting the compound of formula (7) with the appropriate lithium or sodium thioalkoxide in THF at the reflux temperature), and subsequent deprotection using conventional methods well known to those skilled in the art, leads to the corresponding compounds of formula I wherein X is  $SR^3$ . Alternatively, displacement with an amine, for example, by reacting the compound of formula (7) with one equivalent of the appropriate amine of the formula  $R^1NH_2$  in THF at the reflux temperature, followed by deprotection, yields the corresponding compounds of the formula I wherein X is  $NHR^1$ .

[0042] Compounds of the formula I wherein X is halogen can be obtained from the corresponding compounds of formula (7) by displacement with the appropriate metal halide and subsequent deprotection using conventional methods well known to those of skill in the art.

[0043] The compounds of formula I that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the active base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.

[0044] Those compounds of formula I that are acidic in nature are capable of forming base salts with various pharmaceutically acceptable cations. Examples of such salts include the alkali metal and alkaline earth metal salts and, particularly, the sodium and potassium salts. These salts can be prepared by conventional techniques. The chemical bases that are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those that form non-toxic base salts with the acidic compounds of formula I. Such non-toxic base salts include those derived from such pharmaceutically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmaceutically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness, as described above. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final products.

[0045] Compounds of the formula I and their pharmaceutically acceptable salts (hereinafter "the active compounds used in this invention") are useful in the treatment of disorders of human pigmentation, including solar and simple lentigines (including age/liver spots), melasma/chloasma and postinflammatory hyperpigmentation. Such compounds reduce skin melanin levels by inhibiting the production of melanin whether the latter is produced constitutively or in response to UV irradiation (such as sun exposure). Thus, the active compounds used in this invention can be used to

reduce skin melanin content in non-pathological states so as to induce a lighter skin tone, as desired by the user. They can also be used in combination with skin peeling agents (including glycolic acid or trichloroacetic acid face peels) to lighten skin tone and prevent repigmentation.

**[0046]** The active compounds used in this invention can also be used in combination with sunscreens (UVA or UVB blockers) to prevent repigmentation, to protect against sun or UV-induced skin darkening or to enhance their ability to reduce skin melanin and their skin bleaching action. Such compounds can also be used in combination with retinoic acid or its derivatives or any compounds that interact with retinoic acid receptors and accelerate or enhance the invention's ability to reduce skin melanin and skin bleaching action.

**[0047]** The active compounds used in this invention can also be used in combination with ascorbic acid, its derivatives and ascorbic-acid based products (such as magnesium ascorbate) or other products with an anti-oxidant mechanism (such as resveratrol) which accelerate or enhance their ability to reduce skin melanin and their skin bleaching action.

**[0048]** This invention relates both to methods of lightening or reducing the pigmentation of skin in which the compound of formula I, or pharmaceutically acceptable salt thereof, and one or more of the other active ingredients referred to above are administered together, as part of the same pharmaceutical composition, as well as methods in which they are administered separately as part of an appropriate dose regimen designed to obtain the benefits of the combination therapy. The appropriate dose regimen, the amount of each dose administered, and specific intervals between doses of each active agent will depend upon the specific combination of active agents employed, the condition of the patient being treated, and the nature and severity of the disorder or condition being treated. Such additional active ingredients will generally be administered in amounts less than or equal to those for which they are effective as single topical therapeutic agents. The FDA approved dosages for such active agents that have received FDA approval for administration to humans are publicly available.

**[0049]** The active compounds of the present invention are generally administered in the form of pharmaceutical compositions comprising at least one of the compounds of the formula (I), together with a pharmaceutically acceptable vehicle or diluent. Such compositions are generally formulated in a conventional manner utilizing solid or liquid vehicles or diluents as appropriate for topical administration, in the form of solutions, gels, creams, jellies, pastes, lotions, ointments, salves and the like.

**[0050]** Examples of vehicles for application of the active compounds of this invention include an aqueous or water-alcohol solution, an emulsion of the oil-in-water or water-in-oil type, an emulsified gel, or a two-phase system. Preferably, the compositions according to the invention are in the form of lotions, creams, milks, gels, masks, microspheres or nanospheres, or vesicular dispersions. In the case of vesicular dispersions, the lipids of which the vesicles are made can be of the ionic or nonionic type, or a mixture thereof.

**[0051]** In the depigmenting compositions according to the present invention, the concentration of the active compounds of the invention is generally between 0.01 and 10%, preferably between 0.1 and 10%, relative to the total weight of the composition.

**[0052]** The compositions of this invention can optionally also contain a moisturizer, a surfactant, keratolytic, an anti-inflammatory agent, a complexing agent, an antioxidant, a preservative, a fragrance, or a sunscreen.

**[0053]** The ability of compounds of the formulae I to inhibit tyrosinase may be determined using any of the following procedures.

#### 1. Tyrosinase (DOPA oxidase) assay using cell lysate:

**[0054]** Human melanoma cell line, SKMEL 188 (licensed from Memorial Sloan-Kettering), is used in the cell lysate assay and the screen. In the assay, compounds and L-dihydroxyphenylalanine (L-DOPA) (100  $\mu$ g/ml) are incubated with the cell lysates containing human tyrosinase for 8 hours before the plates are read at 405 nm. Potency of the compounds in DOPA oxidase assay is correlated very well with that in tyrosine hydroxylase assay using 3H-tyrosine as a substrate. 4-Cyclohexylresorcinol, when tested in this assay, exhibited an  $IC_{50}$  of 0.3  $\mu$ M.

#### 2. Melanin assay in human primary melanocytes:

**[0055]** Compounds are incubated with human primary melanocytes in the presence of  $\alpha$ -melanocyte stimulating hormone ( $\alpha$ -MSH) for 2-3 days. Cells are then lysed with sodium hydroxide and sodium dodecyl sulfate (SDS) and melanin signals are read at 405 nm. Alternatively,  $^{14}$ C-DOPA is added to the cells in combination with tyrosinase inhibitors and acid-insoluble  $^{14}$ C-melanin is quantitated by a scintillation counter.  $IC_{50}$ 's reflect the inhibitory potency of the compounds in the new melanin synthesis which was stimulated by  $\alpha$ -MSH.

#### 3. Tyrosine kinase assay (TK):

**[0056]** TK assays can be performed using purified tyrosine kinases domain of c-met, erb-B2 or IGF-r. A specific

antibody against phosphorylated tyrosine residue is used in the assay. Colorimetric signals are generated by horse radish peroxidase, which is conjugated to the antibody.

#### 4. Human skin equivalent model:

[0057] A mixture of human melanocytes and keratinocytes is grown in an air-liquid interphase. This tissue culture forms a three dimensional structure that histologically and microscopically resembles the human skin epidermis. Test compounds are added on top of the cells to mimic topical drug application. After incubation with the compounds (10  $\mu$ M) for 3 days, the cells are washed extensively and lysed for DOPA oxidase assay.

#### 5. IL-1 assay (Interleukin-1 assay):

[0058] An IL-1 $\alpha$  ELISA assay (R&D system) can be used to evaluate the effect of compounds on IL-1 secretion in a human skin equivalent model. IL-1 $\alpha$  is a pro-inflammatory cytokine and plays a role in UV-induced skin inflammation.

#### 6. In vivo study:

[0059] Black or dark brown guinea pigs with homogeneous skin color can be used in this study. A solution of the test compound of formula I (5% in ethanol:propylene glycol, 70:30) and the vehicle control are applied to the animals twice daily, 5 days per week for 4-8 weeks. Using this assay, depigmentation of skin was visualized using 5% 4-cyclohexylresorcinol or 5% 4-cyclopentylresorcinol as the test compound.

[0060] The present invention is illustrated by the following examples. It will be understood, however, that the invention is not limited to the specific details of these examples. Melting points are uncorrected. Proton nuclear magnetic resonance spectra ( $^1\text{H}$  NMR) were measured for solutions in  $d_6$ -DMSO and peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane (TMS). The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad.

### EXAMPLES

#### Example 1

##### 4-Cyclohexylresorcinol

[0061] Resorcinol (2.2 g, 20 mmol) and cyclohexanol (6.33 ml, 6g, 60mmol) were suspended in 85% polyphosphoric acid (8 ml). The mixture was heated to 125°C for 24 hours, after which time TLC appeared to show complete consumption of the starting materials. On cooling the mixture was partitioned between water (50 ml) and diethyl ether (50 ml). The aqueous layer was discarded, and the organic portion extracted with sodium hydroxide solution (2 x 50 ml, 2M). The base extract was washed with ether (3 x 50 ml), and then acidified with aqueous hydrochloric acid (120 ml, 2M). The organic components were then extracted into diethyl ether (2 x 50 ml), dried (magnesium sulfate), filtered and the solvent removed under reduced pressure. The resulting brown oil was then chromatographed on silica gel, eluting with ethyl acetate/petroleum ether (bp 60-80°C) 1:2 to give the desired product as an off-white solid (1.7 g, 44%).

[0062]  $^1\text{H}$  NMR (250 MHz,  $d_6$ -DMSO):  $\delta$  1.13-1.34 (5H, m); 1.65-1.71 (5H, m); 2.67-2.75 (1H, m); 6.11 (1H, dd  $J=8.3, 2.4$  Hz); 6.22 (1H, d,  $J=2.4$  Hz); 6.79 (1H, d,  $J=8.3$  Hz); 8.90 (1H, s); 9.00 (1H, s).

[0063] M/Z (ES-ve) gives 191.5 (M-H).

[0064] The following compounds were prepared in a similar manner:

#### Example 2

##### 4-Cyclopentylresorcinol

[0065] From cyclopentanol as a white solid.

[0066]  $^1\text{H}$  NMR (250 MHz,  $d_6$ -DMSO):  $\delta$  1.34-1.75 (6H, m); 1.78-1.88 (2H, m); 3.06 (1H, quint,  $J=9.5$  Hz); 6.12 (1H, dd,  $J=2.4, 8.2$  Hz); 6.22 (1H, d,  $J=2.4$  Hz); 6.83 (1H, d,  $J=8.3$  Hz); 8.91 (1H, s); 9.01 (1H, s).

[0067] M/Z (ES-ve) gives 177.5 (M-H).

Example 34-(1-Methyl-1-cyclopentyl)resorcinol.

5 [0068] From 1-methylcyclopentanol as a solid.

[0069] <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>-MeOH): δ 1.31 (3H, s); 1.74-1.89 (4H, m); 1.94-2.03 (4H, m); 6.33-6.34 (1H, m); 6.39 (1H, dd, J = 2.5, 8.4 Hz); 7.10 (1H, m).

[0070] M/Z (ES-ve) gives 191.6 (M-H).

10 Example 44-(1-Methyl-1-cyclohexyl)resorcinol.

[0071] From 1-methylcyclohexanol as an orange oil. Data reported for a 1:1 mixture of conformers.

15 [0072] <sup>1</sup>H NMR (250 MHz, d<sub>6</sub>-DMSO): δ 1.20-1.80 (9H, m); 1.97 (3H, s); 2.60-3.00 (1H, m); 6.10-6.14 (1H, m); 6.22-6.70 (1H, m); 6.67-6.85 (1H, m); 8.89-8.90 (1H, m); 8.98-9.02 (1H, m).

[0073] M/Z (ES-ve) gives 411.6 (2M-H).

20 Example 54-Cycloheptylresorcinol.

[0074] From cycloheptanol as an orange oil. Data reported for a 1:1 mixture of conformers.

25 [0075] <sup>1</sup>H NMR (250 MHz, d<sub>6</sub>-DMSO): δ 1.30-1.80 (12H, m); 2.60-2.90 (1H, m); 6.08-6.13 (1H, m); 6.20-6.22 (1H, m); 6.78-6.88 (1H, m); 8.86-8.87 (1H, m); 8.89-8.98 (1H, m).

[0076] M/Z (ES-ve) gives 205.5 (M-H).

30 Example 64-Cyclooctylresorcinol.

[0077] From cyclooctanol as an orange oil. Data reported for a 1:1 mixture of conformers.

35 [0078] <sup>1</sup>H NMR (250 MHz, d<sub>6</sub>-DMSO): δ 1.20-1.80 (14H, m); 2.68-3.00 (1H, m); 6.09-6.15 (1H, m); 6.21-6.23 (1H, m); 6.73-6.84 (1H, m); 8.80-8.83 (1H, m); 8.90-9.00 (1H, m).

[0079] M/Z (ES-ve) gives 219.6 (M-H).

Example 7In Vivo Test Data

40

[0080] In vivo experiments were carried out to determine the depigmenting effects of 4-cyclohexylresorcinol and 4-cyclopentylresorcinol using the assay described above (in vivo study). Thus, 5% 4-cyclohexylresorcinol and 5% 4-cyclopentylresorcinol, each in ethanol:propylene glycol (70:30), were administered separately to the ears of black guinea pigs. Depigmentation was determined by subtracting the light reflectance of untreated ears from the light reflectance of treated ears. As shown by the data in the Table below, both test compositions reduced pigmentation in treated ears starting 3 weeks after initial treatment. The depigmentation effect was reversible, and repigmentation partially resumed one week after ceasing treatment.

50

55

TABLE


Depigmentation Effect Of Selected Compounds <sup>a</sup>				
Animal	3-week	6-week	8.5 week	1 week post-treatment
4-cyclohexylresorcinol				
1A	13	8	6	*
1B	0	0	7	1
1C	14	14	19	*
1D	3	7	7	0
4-cyclopentylresorcinol				
3B	15	12	10	6
3C	9	9	18	*
3D	4	9	7	*

<sup>a</sup> Depigmentation was determined by  $\Delta$  light reflectance, which is calculated as (light reflectance of treated ear) - (light reflectance of untreated ear). Positive value indicates depigmentation effect.

\* euthanized

### Claims

1. A topical pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising an amount of a compound of the formula I,



wherein X is hydrogen, OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above;

n is 0 to 3; and


the dashed line represents an optional double bond;

or a pharmaceutically acceptable salt thereof, that is effective in lightening skin or reducing the pigmentation of skin, and a pharmaceutically acceptable carrier.

2. The topical pharmaceutical composition of claim 1, wherein the compound of formula I is 4-cyclohexylresorcinol.
3. The topical pharmaceutical composition of claim 1, wherein the compound of formula I is 4-cyclopentylresorcinol.
4. A method of lightening skin or reducing the pigmentation of skin in a human, comprising administering to said human an amount of a compound of the formula I.

5

10



15

wherein X is hydrogen; OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above:

n is 0 to 3; and

the dashed line represents an optional double bond:

20

or a pharmaceutically acceptable salt thereof, that is effective in lightening skin or reducing the pigmentation of skin.

5. The method of claim 4, wherein the compound of formula I is 4-cyclohexylresorcinol.


25

6. The method of claim 4, wherein the compound of formula I is 4-cyclopentylresorcinol.

7. A topical pharmaceutical composition for inhibiting tyrosinase in a human, comprising a tyrosinase inhibiting effective amount of a compound of the formula I.

30

35



40

45

wherein X is hydrogen; OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above:

n is 0 to 3; and

the dashed line represents an optional double bond:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

50

8. The topical pharmaceutical composition of claim 7, wherein the compound of formula I is 4-cyclohexylresorcinol.


9. The topical pharmaceutical composition of claim 7, wherein the compound of formula I is 4-cyclopentylresorcinol.

55

10. A method of inhibiting tyrosinase in a human, comprising administering to said mammal a tyrosinase inhibiting effective amount of a compound of the formula I.

5

10



15

wherein X is hydrogen; OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above;

n is 0 to 3; and

the dashed line represents an optional double bond;

20

or a pharmaceutically acceptable salt thereof.

11. The method of claim 10, wherein the compound of formula I is 4-cyclohexylresorcinol.


12. The method of claim 10, wherein the compound of formula I is 4-cyclopentylresorcinol.

25

13. A topical pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising a tyrosinase inhibiting effective amount of a compound of the formula I,

30

35



40

wherein X is hydrogen; OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above;

45

n is 0 to 3; and

the dashed line represents an optional double bond;

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

50

14. The topical pharmaceutical composition of claim 13, wherein the compound of formula I is 4-cyclohexylresorcinol.


15. The topical pharmaceutical composition of claim 13, wherein the compound of formula I is 4-cyclopentylresorcinol.

16. A method of lightening skin or reducing the pigmentation of skin in a human, comprising administering to said human a tyrosinase inhibiting effective amount of a compound of the formula I.

55

5

10



15

wherein X is hydrogen; OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above:  
 n is 0 to 3; and  
 the dashed line represents an optional double bond;  
 or a pharmaceutically acceptable salt thereof.

20

17. The method of claim 16, wherein the compound of formula I is 4-cyclohexylresorcinol.

18. The method of claim 16, wherein the compound of formula I is 4-cyclopentylresorcinol.

25

19. A composition according to claim 1, which further comprises a sunscreen.

20. A composition according to claim 1, further comprising resveratrol or another active agent that is an anti-oxidant.

30

21. A composition according to claim 1, further comprising retinoic acid or a derivative of retinoic acid.

22. A composition according to claim 1, further comprising glycolic acid, trichloroacetic acid or another skin peeling agent.


35

23. A composition according to claim 1, in the form of a lotion, cream or ointment.

24. A topical or transdermal pharmaceutical composition for treating an inflammatory disorder in a human, comprising an amount of a compound of the formula I.

40

45



50

55

wherein X is hydrogen; OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above:  
 n is 0 to 3; and  
 the dashed line represents an optional double bond;




or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder, and a pharmaceutically acceptable carrier.

25. The composition of claim 24, wherein the compound of formula I is 4-cyclohexylresorcinol.

26. The composition of claim 24, wherein the compound of formula I is 4-cyclopentylresorcinol.

27. A method of treating an inflammatory disorder in a human, comprising administering to said human an amount of a compound of the formula I.



wherein X is hydrogen; OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above;

n is 0 to 3; and


the dashed line represents an optional double bond;

or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.

28. The method of claim 27, wherein the compound of formula I is 4-cyclohexylresorcinol.

29. The method of claim 27, wherein the compound of formula I is 4-cyclopentylresorcinol.

30. A topical or transdermal pharmaceutical composition for treating an inflammatory disorder in a human, comprising a tyrosinase inhibiting effective amount of a compound of the formula I,




wherein X is hydrogen; OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above;

n is 0 to 3; and

the dashed line represents an optional double bond;

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

31. The composition of claim 30, wherein the compound of formula I is 4-cyclohexylresorcinol.
32. The composition of claim 30, wherein the compound of formula I is 4-cyclopentylresorcinol.
- 5 33. A method of treating an inflammatory disorder in a human, comprising administering to said human a tyrosinase inhibiting effective amount of a compound of the formula I.



- 25 wherein X is hydrogen; OR<sup>1</sup>, wherein R<sup>1</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; OCOR<sup>2</sup> wherein R<sup>2</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl or phenyl; halogen; (C<sub>1</sub>-C<sub>6</sub>)alkyl; aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; SR<sup>3</sup> wherein R<sup>3</sup> represents hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl; or NHR<sup>1</sup> wherein R<sup>1</sup> is defined as above;
- 30 n is 0 to 3; and
- the dashed line represents an optional double bond;
- or a pharmaceutically acceptable salt thereof.

34. The method of claim 33, wherein the compound of formula I is 4-cyclohexylresorcinol.
35. The method of claim 33, wherein the compound of formula I is 4-cyclopentylresorcinol.



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 98 30 7523

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	WO 91 11119 A (ENZYTECH INC) 8 August 1991 * page 8, line 1-6 * * page 19, line 22 - line 32 * * page 34: table 1 * * claims 1-6 *	1,2	A61K7/48 A61K31/05
A	DATABASE WPI Section Ch, Week 9307 Derwent Publications Ltd., London, GB; Class D21, AN 93-055163 XP002087694 & JP 05 004905 A (POLA CHEM IND INC) , 14 January 1993 * abstract *	1-19	
A	PATENT ABSTRACTS OF JAPAN vol. 016, no. 470 (C-0990), 30 September 1992 & JP 04 169511 A (POLA CHEM IND INC;OTHERS: 01), 17 June 1992 * abstract *	24-35	
A	US 5 399 785 A (MIURA YASUTAKA ET AL) 21 March 1995 * abstract * * column 1, line 5 - line 9 *	7,10,13, 16	A61K
A	EP 0 623 339 A (L'OREAL) 9 November 1994 * page 2, line 33 - line 36 *	1-18	
D,A	EP 0 341 664 A (KURARAY CO) 15 November 1989 * claim *	1	
The present search report has been drawn up for all claims			
Place of search <b>BERLIN</b>		Date of completion of the search <b>14 December 1998</b>	Examiner <b>Pelli Wablat, B</b>
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1603/03 12 (Pst/CO1)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 30 7523

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-12-1998

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9111119 A	08-08-1991	US 5059438 A	22-10-1991
		AT 109626 T	15-08-1994
		AU 7321291 A	21-08-1991
		CA 2074352 A	06-08-1991
		DE 69103406 D	15-09-1994
		DE 69103406 T	20-04-1995
		DK 514467 T	02-01-1995
		EP 0514467 A	25-11-1992
		ES 2063497 T	01-01-1991
		US 5202141 A	13-04-1993
		US 5304679 A	19-04-1994
US 5399785 A	21-03-1995	JP 6100433 A	12-04-1994
EP 0623339 A	09-11-1994	FR 2704428 A	04-11-1994
		DE 69404373 D	04-09-1997
		DE 69404373 T	22-01-1998
		ES 2105551 T	16-10-1997
		JP 2696482 B	14-01-1998
EP 0341664 A	15-11-1989	JP 7316034 A	05-12-1995
		JP 1921849 C	07-04-1995
		JP 2049715 A	20-02-1990
		JP 6051619 B	06-07-1994
		JP 7002643 A	06-01-1995
		US 4959393 A	25-09-1990